Noronha V, Patil VM, Joshi A, et al. - Researchers investigated if the addition of pemetrexed and carboplatin chemotherapy to an oral tyrosine kinase inhibitor could lead to improved outcomes in patients with advanced non–small-cell lung cancer (NSCLC) harboring an EGFR-sensitizing mutation. From 2016 to 2018, they randomly assigned 350 patients to gefitinib 250 mg orally per day (Gef; n = 176) and gefitinib 250 mg orally per day plus pemetrexed 500 mg/m² and carboplatin area under curve 5 intravenously every 3 weeks for four cycles, followed by maintenance pemetrexed (gefitinib plus chemotherapy [Gef+C]; n = 174). Outcomes revealed significantly prolonged progression-free survival and overall survival in correlation with the addition of pemetrexed and carboplatin chemotherapy to gefitinib but with increased toxicity in patients with NSCLC.